Bibliographic Details
| Title: |
Prevalence of acquired and transmitted HIV drug resistance in Iran: a systematic review and meta-analysis |
| Authors: |
Hossein Mirzaei, Sana Eybpoosh, Fatemeh Mehrabi, Mohammad Reza Shojaei, Ali Mirzazadeh, Mehrdad Khezri, Naser Nasiri, Hamid Sharifi |
| Source: |
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-13 (2024) |
| Publisher Information: |
BMC, 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Infectious and parasitic diseases |
| Subject Terms: |
Anti-retroviral agents, Drug resistance, Viral, HIV infections, Treatment failure, Infectious and parasitic diseases, RC109-216 |
| More Details: |
Abstract Background There is no systematic review on the prevalence of HIV drug resistance (HIVDR) in Iran. We aimed to estimate the prevalence of HIVDR among people living with HIV (PLHIV) in Iran. We assessed HIVDR prevalence in antiretroviral therapy (ART) naïve PLHIV (i.e., those without a history of ART) and PLHIV receiving ART. Method We systematically searched Scopus, PubMed, Web of Science, Embase, Iranian databases (Iranian Medical Research Information System, Magiran, and Scientific Information Database), the references of studies, and Google Scholar until March 2023. A random-effects model was used to calculate a point estimate and 95% confidence interval (95% CI) for the prevalence of HIVDR in PLHIV. Results Among 461 potential publications, 22 studies were included in the meta-analysis. The pooled prevalence of acquired HIVDR in PLHIV receiving ART was 34% (95% CI: 19, 50) for nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), 27% (95% CI: 15, 41) for non-nucleoside reverse transcriptase inhibitors (NNRTIs), and 9% (95% CI: 3, 18) for protease inhibitors (PIs). The pooled prevalence of acquired HIVDR in treatment failure PLHIV was 50% (95% CI: 31, 69) for NRTIs, 49% (95% CI: 29, 69) for NNRTIs, 11% (95% CI: 2, 24) for PIs, and 1% (95% CI: 0, 4) for integrase inhibitors (INIs). The pooled prevalence of transmitted HIVDR in ART-naïve people was 3% (95% CI; 1, 6) for NRTIs, 5% (95% CI: 2, 9) for NNRTIs, and 0 for PIs and INIs. Conclusion The prevalence of HIVDR was relatively high in both ART-naïve PLHIV and those receiving ART. Without universal pretreatment HIVDR testing and more frequent routine HIV viral load testing among PLHIV who are on ART, the HIVDR prevalence might increase in PLHIV in Iran. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1471-2334 |
| Relation: |
https://doaj.org/toc/1471-2334 |
| DOI: |
10.1186/s12879-023-08916-3 |
| Access URL: |
https://doaj.org/article/cea8b1341eb0448f8b4c0a9de49571eb |
| Accession Number: |
edsdoj.8b1341eb0448f8b4c0a9de49571eb |
| Database: |
Directory of Open Access Journals |
|
Full text is not displayed to guests. |
Login for full access.
|
